feedback

Course Director

Andre H. Goy, MD
Andre H. Goy, MD

John Theurer Cancer Center
Regional Cancer Care Associates
Georgetown University
Seton Hall
Hackensack Meridian School of Medicine
Hackensack, New Jersey

Faculty

Richard R. Furman
Richard R. Furman, MD

Weill Cornell Medicine
New York, New York

Krish Patel
Krish Patel, MD

Swedish Cancer Institute
Center for Blood Disorders and Stem Cell Transplantation
Seattle, Washington

Deborah M. Stephens
Deborah M. Stephens, DO

University of Utah/Huntsman Cancer Institute
Salt Lake City, Utah

Accredited by

Medical Learning Institute, Inc.

Activity Description

First- and second-generation Bruton tyrosine kinase (BTK) inhibitors have transformed the therapeutic landscape of several lymphoid cancers, including chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). The present and future management of these diseases will increasingly be defined by the integration of BTK inhibitors—along with other novel therapeutics—into management protocols that have previously been characterized by the use of immunochemotherapy-focused options. Several important practical issues arising from the use of BTK inhibitors, ranging from the initial therapy selection to therapeutic sequencing and use of active combinations, will continue to be a part of patient management for years to come.

This PeerView Live “How I Think, How I Treat” on-demand activity, based on a satellite symposium preceding the 61st ASH Annual Meeting and Exposition, exposes learners to the personal insights of several experts in the field and includes in-depth analyses of the cutting-edge science on the present and future role of BTK inhibitors in CLL, MCL, and other lymphoid cancers. Key topics include BTK inhibitor sequencing, selecting patients for treatment, differentiating among first- and second-generation compounds, and safety management. Ultimately, this event provides a “virtual mentorship” experience on the use of BTK inhibitors in several different diseases.

Target Audience

The activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, and other clinicians involved in the management of patients with B-cell malignancies.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Describe updated evidence regarding the use of first- and second-generation BTK inhibitors in the management of B-cell NHL, including agent potency/selectivity, response data, survival outcomes, and activity in BTK inhibitor–intolerant or –resistant disease
  • Recommend personalized therapy with BTK inhibitors for patients across the spectrum of B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, among others
  • Manage unique safety considerations associated with BTK inhibitor therapy in patients with B-cell NHL

Providership, Credit, and Support

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by an independent educational grant from AstraZeneca.

Physician Continuing Medical Education


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosures

Chair
Andre H. Goy, MD
Chairman & Executive Director
Lymphoma Division Chief – John Theurer Cancer Center
Chief Science Officer – Regional Cancer Care Associates
Lydia T. Pfund Chair for Lymphoma
Professor of Medicine – Georgetown University
Professor and Chair, Dept. of Oncology, Seton Hall
Hackensack Meridian School of Medicine
Hackensack, New Jersey

Andre H. Goy, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acerta Pharma; Celgene Corporation; Janssen Pharmaceuticals, Inc.; and Kite Pharma, Inc./Gilead.
Grant/Research Support from Acerta Pharma; AstraZeneca; Bayer; CALGB (Cancer and Leukemia Group B); Celgene Corporation; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Kite Pharma, Inc.; MD Anderson; MorphoSys; and Pharmacyclics LLC.
Other financial interest/relationship Board Member and shareholder for COTA.

Faculty
Richard R. Furman, MD
Morton Coleman, M.D. Distinguished Professor of Medicine
Weill Cornell Medicine
New York, New York

Richard R. Furman, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Acerta Pharma; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Oncotracker; Pharmacyclics LLC; Sunesis Pharmaceuticals.; TG Therapeutics, Inc.; and Verastem.
Grant/Research Support from Acerta Pharma; AstraZeneca; Janssen Pharmaceuticals, Inc.; and TG Therapeutics, Inc.
Data Safety Monitoring Board for Incyte Corporation.
Other financial interest/relationship Speaker fee from AbbVie and Janssen Pharmaceuticals, Inc.

Krish Patel, MD
Director, Lymphoma Program
Swedish Cancer Institute
Center for Blood Disorders and Stem Cell Transplantation
Seattle, Washington

Krish Patel, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Celgene Corporation; Genentech; Pharmacyclics/Janssen; and Sunesis Pharmaceuticals.
Grant/Research Support from AstraZeneca.
Speakers Bureau participant with AstraZeneca; Celgene Corporation; Genentech; and Pharmacyclics/Janssen.

Deborah M. Stephens, DO
Assistant Professor
Division of Hematology and Hematologic Malignancies
University of Utah/Huntsman Cancer Institute
Salt Lake City, Utah

Deborah M. Stephens, DO, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Acerta Pharma; Gilead; and Karyopharm.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewer has nothing to disclose:
Natalie I. Vokes, MD

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.